MicroCoil treatment for aneurysms to enter trials:
This article was originally published in Clinica
Executive Summary
Micrus is to begin US clinical trials of its minimally invasive treatment for intracranial aneurysms under an investigational device exemption from the FDA. The ACT MicroCoil delivery system releases coils into the aneurysm, which isolate it from arterial flow and reduce its chances of rupture or re-rupture. Rupture of intracranial aneurysms can lead to stroke and death if untreated, said the Mountain View, California based company. Micrus estimated that the worldwide market value of its product could be worth more than $100 million annually.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.